Nautilus and Tribute Sign Deal to Commercialize CAMBIA
According to the company, CAMBIA is approved in the US for the acute treatment of migraine with or without aura and was launched in the US in June 2010.
A novel, water-soluble, buffered diclofenac potassium powder, CAMBIA is the only prescription non - steroidal anti-inflammatory drug (NSAID) available for the acute treatment of migraine, said Nautilus.
Nautilus added that Engineered using Dynamic Buffering Technology (DBT), a patented absorption-enhancing technology developed by APR Applied Pharma Research, CAMBIA is specifically designed for fast, effective relief from the symptoms of migraine.
CAMBIA enters the bloodstream quickly and readily achieves peak plasma concentrations, providing pain relief in fifteen minutes for some patients.
James Fares, chairman and CEO of Nautilus Neurosciences, said: “The management team at Tribute Pharmaceuticals has a wealth of experience in developing, launching and successfully commercializing new products in Canada.
“This partnership along with recent developments in the US has significantly enhanced our ability to market CAMBIA to the broader North American market and reach more people suffering from acute migraine headaches. We look forward to completing the expansion of our efforts through the addition of a partner for the family practice market in the United States in 2011.”
Rob Harris, president and CEO of Tribute Pharmaceuticals, said: “Many Canadians who suffer from migraines are dissatisfied with their current medication and hope for a better treatment. Tribute Pharmaceuticals is very excited about the potential for CAMBIA in Canada and we look forward to building a strong partnership with Nautilus Neurosciences.”
Can Tribute successfully market the product in Canada?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.